scholarly journals Amyloidosis of the Breast with Multicentric DCIS and Pleomorphic Invasive Lobular Carcinoma in a Patient with Underlying Extranodal Castleman’s Disease

2013 ◽  
Vol 2013 ◽  
pp. 1-3 ◽  
Author(s):  
David Chiang ◽  
Michael Lee ◽  
Pauline Germaine ◽  
Lydia Liao

We present an interesting case of focal amyloidosis of the left breast which was intermixed with ductal carcinoma in situ (DCIS). On subsequent staging bilateral breast magnetic resonance imaging (MRI), the patient was found to have an additional suspicious enhancing mass with spiculated borders within the left breast. This mass was biopsy proven to represent pleomorphic invasive lobular carcinoma. A pulmonary nodule within the lingula was also noted on the staging bilateral breast MRI and was biopsy proven to represent extranodal Castleman’s disease. Therefore, it is believed that our patient had secondary amyloidosis due to Castleman’s disease.

2015 ◽  
Vol 18 (1) ◽  
pp. 63 ◽  
Author(s):  
Na Young Jung ◽  
Sung Hoon Kim ◽  
Sung Hun Kim ◽  
Ye Young Seo ◽  
Jin Kyoung Oh ◽  
...  

Author(s):  
Anupama C. ◽  
Anuradha H. V. ◽  
Vinayak V. Maka

Radiation recall dermatitis (RRD) is the appearance of skin reactions in previously irradiated skin which is triggered by the administration of certain drugs. Surgery, chemotherapy, and radiotherapy are the mainstay of treatment in breast cancer. RRD induced by trastuzumab has been rarely reported in India. This is a case report of a 56-year-old woman presented to the medical oncology outpatient department of our hospital with breast lump, and she was diagnosed to have human epidermal growth factor receptor 2 (HER-2/neu) positive invasive ductal carcinoma of left breast of stage T2N3cM0. She was treated with neoadjuvant chemotherapy, and she underwent modified radical mastectomy with axillary lymph node dissection. The treating oncologist was planned to start on adjuvant chemotherapy with injection trastuzumab for every four weeks, for 15 cycles. Patient received first dose of injection trastuzumab (450 mg) intravenously in the right (contralateral) arm and developed painful, swollen, erythematous blisters, and maculopapular rashes following the sharp linear borders of her previous radiation fields. She was reviewed by the medical oncologist and diagnosed as a rare case of RRD and treated with topical betamethasone cream. Causality assessment for RRD to trastuzumab was done using Naranjo and WHO-UMC scale and found to be in the category of probable and probable/ likely respectively.


Author(s):  
Anak Agung Ngurah Gunawan ◽  
I Wayan Supardi ◽  
S. Poniman ◽  
Bagus G. Dharmawan

<p>Medical imaging process has evolved since 1996 until now. The forming of Computer Aided Diagnostic (CAD) is very helpful to the radiologists to diagnose breast cancer. KNN method is a method to do classification toward the object based on the learning data which the range is nearest to the object. We analysed two types of cancers IDC dan ILC. 10 parameters were observed in 1-10 pixels distance in 145 IDC dan 7 ILC. We found that the Mean of Hm(yd,d) at 1-5 pixeis the only significant parameters that distingguish IDC and ILC. This parameter at 1-5 pixels should be applied in KNN method. This finding need to be tested in diffrerent areas before it will be applied in cancer diagnostic.</p>


2002 ◽  
Vol 88 (3) ◽  
pp. 215-223 ◽  
Author(s):  
Anke Heinig ◽  
Dieter Lampe ◽  
Heinz Kölbl ◽  
Rainer Beck ◽  
Sylvia H Heywang-Köbrunner

Aims and Background The value of breast MRI may be impaired by unspecific enhancement. This may leave patients with difficult-to-assess breast tissue with an uncertain diagnosis. We examined whether this unspecific enhancement (which is mostly due to proliferative or hyperplastic changes of benign breast tissue) may be suppressed by antiestrogen medication. Methods In a trial of treatment, 10 peri- or postmenopausal patients who exhibited diffuse and/or focal enhancement on breast MRI before tamoxifen medication agreed to undergo a short-term tamoxifen treatment. MRI monitoring was performed 2, 4 and 8 weeks after onset of antiestrogen therapy (tamoxifen, 30 mg per day). Results Six patients showed a significant decrease of enhancement. Unchanged (n = 3) or increased (n = 1) enhancement was seen in 4 patients. One of the three patients with unchanged enhancement proved to have diffuse lobular carcinoma in situ. Conclusions Part of the unspecific enhancement seen on breast MRI can probably be suppressed by short-term antiestrogen medication.


2016 ◽  
Vol 22 (2) ◽  
pp. 143-150 ◽  
Author(s):  
Muhammad Asad Parvaiz ◽  
Peiming Yang ◽  
Eisha Razia ◽  
Margaret Mascarenhas ◽  
Caroline Deacon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document